Henan Lingrui Pharmaceutical Co (SHSE:600285) Short-Term Debt: ¥361 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600285 Henan Lingrui Pharmaceutical Co Ltd SHSE:600285
97 GF Score
Price ¥19.70
GF Value ¥23.67
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Henan Lingrui Pharmaceutical Co Short-Term Debt?

Henan Lingrui Pharmaceutical Co SHSE:600285 +0.15% 97 Short-Term Debt is ¥361 Mil as of Jun. 2026. GuruFocus rates SHSE:600285 with a GF Score™ of 97/100 and a GF Value™ of ¥23.67 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Henan Lingrui Pharmaceutical Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥361 Mil.

Henan Lingrui Pharmaceutical Co's quarterly Short-Term Debt declined from Dec. 2025 (¥392 Mil) to Mar. 2026 (¥275 Mil) but then increased from Mar. 2026 (¥275 Mil) to Jun. 2026 (¥361 Mil).

Henan Lingrui Pharmaceutical Co's annual Short-Term Debt declined from Dec. 2023 (¥141 Mil) to Dec. 2024 (¥33 Mil) but then increased from Dec. 2024 (¥33 Mil) to Dec. 2025 (¥392 Mil).

Henan Lingrui Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Henan Lingrui Pharmaceutical Co Short-Term Debt Related Terms

Henan Lingrui Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Henan Lingrui Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Henan Lingrui Pharmaceutical Co Short-Term Debt Chart

Henan Lingrui Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 126.34 93.81 141.22 33.28 391.66

Henan Lingrui Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 456.67 516.68 391.66 274.63 361.05
SHSE:600285
97GF Score
Henan Lingrui Pharmaceutical Co Ltd SHSE:600285
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥361 Mil mean?
Henan Lingrui Pharmaceutical Co (SHSE:600285) has a Short-Term Debt of ¥361 Mil as of Jun. 2026.
Is Henan Lingrui Pharmaceutical Co's Short-Term Debt too high?
Henan Lingrui Pharmaceutical Co's current Short-Term Debt is ¥361 Mil. Overall, Henan Lingrui Pharmaceutical Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Henan Lingrui Pharmaceutical Co's Short-Term Debt compare to ZTS?
Henan Lingrui Pharmaceutical Co's Short-Term Debt of ¥361 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Henan Lingrui Pharmaceutical Co's current Short-Term Debt is ¥361 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Lingrui Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co (SHSE:600285) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥23.67, compared to a current price of ¥19.70 — trading 16.8% below its estimated fair value. The current Short-Term Debt is ¥361 Mil. Henan Lingrui Pharmaceutical Co's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Henan Lingrui Pharmaceutical Co (SHSE:600285), the current Short-Term Debt is ¥361 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Henan Lingrui Pharmaceutical Co (SHSE:600285) Overvalued in 2026?

Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥19.70 is trading 16.8% below its estimated GF Value™ of ¥23.67. GuruFocus considers Henan Lingrui Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600285:

  • Short-Term Debt: ¥361 Mil
  • GF Value™: ¥23.67 vs. price of ¥19.70 (16.8% below fair value)
  • GF Score™: 97/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600285 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Henan Lingrui Pharmaceutical Co Business Description

Address No. 59 Jiefang Chengguan Road, Xinxian, Xinyang, Henan, CHN, 465550
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
97GF Score

Get the complete analysis for SHSE:600285

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.70
Price
¥23.67
GF Value